Maybe someone with a better science background could answer something for me. I was wondering if someone treated with one AAV vector would likely develop antibodies that would prevent a different AAV vector from working? If not wouldn't the retreatment option present a nice opportunity for "inferior" regimens of a different type?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.